PTX 100

Drug Profile

PTX 100

Alternative Names: GGTI-2418; PTX-100

Latest Information Update: 26 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; University of South Florida; Yale University
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Prescient Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Geranylgeranyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Multiple myeloma

Most Recent Events

  • 26 Jun 2017 PTX 100 is still at phase I development stage for Solid tumours in USA (unspecified route) (Prescient Therapeutics pipeline, June 2017)
  • 18 Jun 2017 Preclinical development for multiple myeloma is ongoing in USA (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top